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The importance of the priming of the lung environ-
ment by past infections is being increasingly recog-
nized. Exposure to any given antigen can either im-
prove or worsen the outcome of subsequent lung
infections, depending on the immunological history
of the host. Thus, an ability to impart transient alter-
ations in the lung environment in anticipation of fu-
ture insult could provide an important novel therapy
for emerging infectious diseases. In this study, we
show that nasal administration of virus-like particles
(VLPs) before, or immediately after, lethal challenge
with methicillin-resistant Staphylococcus aureus
(MRSA) of mice i) ensures complete recovery from
lung infection and near absolute clearance of bacteria
within 12 hours of challenge, ii) reduces host re-
sponse-induced lung tissue damage, iii) promotes
recruitment and efficient bacterial clearance by
neutrophils and CD11c cells, and iv) protects mac-
rophages from MRSA-induced necrosis. VLP-medi-
ated protection against MRSA relied on innate im-
munity. Complete recovery occurred in VLP-dosed
mice with severe combined immunodeficiency, but
not in wild-type mice depleted of either Ly6G or
CD11c cells. Early IL-13 production associated
with VLP-induced CD11c cells was essential for
VLP-induced protection. These results indicate that
VLP-induced alteration of the lung environment
protects the host from lethal MRSA pneumonia by
enhancing phagocyte recruitment and killing and
by reducing inflammation-induced tissue damage
196via IL-13–dependent mechanisms. (Am J Pathol 2012,
181:196–210; http://dx.doi.org/10.1016/j.ajpath.2012.03.018)
The immune system is a plastic entity, in which the history
of prior exposures modulates responses to future insults.
It is well documented that the occurrence and even the
exact sequence of infections can skew the immune re-
sponse to a subsequent threat toward an inflammatory or
anti-inflammatory phenotype,1–5 depending on the type
of insult,1,5 its location,6 and even the stage of host de-
velopment.2 The modulatory effect of former insults can
be long lasting and can influence the outcome and prog-
nosis of an individual long after the infection has been
cleared.2,7 For example, acute influenza infection can
decrease immune-mediated lung damage associated
with subsequent respiratory syncytial virus infection and
inhibit replication of vaccinia virus, but it can also en-
hance replication of lymphocytic choriomeningitis virus
and murine cytomegalovirus.7 Microbial products, such
as CpG, lipopolysaccharide, or other bacterial toxins,
can induce protection against a variety of subsequent
respiratory pathogens.8–10 The homeostatic profile of the
lung can also be altered by noninfectious substances.
Morphine reduces Toll-like receptor 9–NF-B signaling,
which leads to impaired clearance of Streptococcus
pneumoniae.11 Cigarette smoke down-regulates Toll-like
receptor 2 expression on alveolar macrophages (AMs)12
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which may increase susceptibility to respiratory bacterial
infections. Immune imprinting by the nontoxic heat-labile
endotoxin (LTK63) of Escherichia coli, delivered as a mu-
cosal adjuvant, induces a transient inflammatory re-
sponse that reduces inflammation to subsequent type 1
and 2 helper T-cell pathogens (namely, influenza, respi-
ratory syncytial virus, and Cryptococcus neoformans).9
Therefore, the ability to transiently modulate the immune
environment in preparation for a future infectious chal-
lenge, without the need for the induction of harmful in-
flammation, would be beneficial as preventative and ther-
apeutic treatments.
We have previously reported that pulmonary delivery
of a noninfectious, self-assembled protein cage nanopar-
ticle (PCN) induced low-grade inflammation in the ab-
sence of tissue damage, yet it enhanced the protection of
mice against subsequent sublethal and lethal infections
by unrelated viruses, including influenza, severe acute
respiratory syndrome virus, and pneumovirus.14 This pro-
tection is associated with the formation of inducible bron-
chus-associated lymphoid tissue (iBALT) that modulates
the local lung environment in the absence of harmful
inflammation.14,15
PCN is a hollow, spherical protein cage that self-as-
sembles from 24 identical subunits of small heat shock
protein, derived from Methanocaldococcus jannaschii. Al-
though PCNs are not of viral origin, their small size
(12-nm diameter), self-assembled particulate structure,
immunogenicity, and lack of genetic material character-
ize them as virus-like particles (VLPs).14,16,17 Known for
their potent adjuvant-like properties,18 VLPs can enhance
immune responses to parental infectious agents, such as
hepatitis C,19 dengue virus,20 Norwalk virus,21,22 or hu-
man papillomavirus-induced cervical cancer.23,24 In ad-
dition, VLPs have been used as a platform for targeting
cells16 and as a delivery vehicle to present the immune
system with fused or conjugated heterologous epitopes,25
and even to induce autoantibodies to self molecules in-
volved in chronic diseases.25,26 The work reported by our
laboratory adds yet another dimension to the VLP-mediated
immune modulation (namely, the ability to induce protective
immunity to a variety of unrelated antigens).14
Invasivemethicillin-resistantStaphylococcus aureus (MRSA)
infections result annually in more deaths (18,000 cases)
than any other single infectious agent in the United States.27
In fact, the mortality associated with MRSA exceeds the
mortality resulting from combined, human immunodefi-
ciency, hepatitis, and influenza viruses.28,29 The pulsed-
field gel electrophoresis type USA300 is the most prevalent
community-associated MRSA strain in United States.
USA300 typically causes skin and soft tissue infections;
however, it is also capable of causing severe staphylococ-
cal diseases, including necrotizing pneumonia that can
transpire in otherwise healthy individuals.30,31
In the current study, PCN administration before, or
shortly after, respiratory infection of mice with MRSA min-
imized morbidity and prevented mortality. Major reduc-
tion of bacterial burden was observed as early as 8 hours
after infection in PCN-dosed mice. This protection was
associated with improved recruitment of neutrophils andenhanced antibacterial activity of both neutrophils and
lung CD11c cells. The reliance on innate immunity for
PCN-mediated protection was indicated by the complete
recovery of MRSA-infected mice with severe combined
immunodeficiency (SCID) dosed with PCN and the sig-
nificant loss of protection in PCN-dosed wild-type (WT)
mice depleted of either Ly6G neutrophils or CD11c
cells. Interestingly, PCN-mediated protection was not lim-
ited to the lung, because bone marrow (BM) cells from
mice intranasally dosed with PCN, but not with PBS,
efficiently killed MRSA in vitro. Phenotypical analyses re-
vealed that PCN-dosed mice retained a high M1:M2 mac-
rophage ratio throughout the infection; however, the effi-
cient bacterial killing in PCN-dosed mice was dependent
on the early presence of IL-13 and IL-4, in that mice
deficient in either of these cytokines had reduced PCN-
mediated protection against MRSA pneumonia.
Materials and Methods
Mice
Male and female WT BALB/c, C57BL/6 (CD45.2), SCID,
C-X-C chemokine receptor (CXCR) 2 knockout (KO),
IL-13 KO, and CCR2 KO mice were bred at Montana
State University, Bozeman. The breeding pairs of IL-13
KO mice were originally generated by Dr. Andrew N.J.
McKenzie (Medical Research Council, Laboratory of Mo-
lecular Biology, Cambridge, UK) and were kindly pro-
vided by Dr. Andrij Holian (University of Montana, Mis-
soula). The breeding pairs of WT and remaining KO mice
were obtained from The Jackson Laboratories (Bar Har-
bor, MI). All mice were maintained at Montana State Uni-
versity Animal Resources Center in individual ventilated
cages under high efficiency particulate arresting-filter
barrier conditions and were fed sterile food and water ad
libitum. All animal care procedures were in accordance
with institutional polices for animal health and well-being;
7- to 8-week-old mice were used in all experiments.
Administration of Nanoparticles
PCNs were prepared as previously described.14,16 Mice
were lightly anesthetized with oxygen-delivered isoflu-
rane, USP (Piramal, Bethlehem, PA), and were intrana-
sally dosed with 50 L of sterile PBS or PCN containing
100 g of protein. This dosing procedure was repeated
five times either daily or every couple of days for 2 weeks,
as designated in the figures.
MRSA Infection
The LAC strain of MRSA (pulsed-field type USA300) was
a kind gift from Dr. Jovanka Voyich (Montana State Uni-
versity). The USA300 MRSA was used for infections be-
cause it has been described as a causative agent of
severe community-onset pneumonia in healthy individu-
als.32 Before MRSA infection, PCN- and PBS-dosed mice
were rested for 6 to 7 days to ensure removal of nano-
particles from the body.17 Fresh or frozen bacteria grown
198 Rynda-Apple et al
AJP July 2012, Vol. 181, No. 1to OD600 1.5 in tryptic soy broth were used for in vivo infec-
tions and in vitro cultures. Between 5  107 and 5  108
(where indicated) microorganisms were used for the infec-
tion dose. The erythromycin-sensitive MRSA strain (AH1263
USA300 community-associated MRSA ErmS Lac)33 was
provided by Dr. Alex Horswill (University of Iowa, Iowa City).
Collection and Preparation of BALF
Mice were sacrificed at the designated time points by i.p.
administration of a lethal dose of sodium pentobarbital
(90 mg/kg), followed by exsanguination when the mice no
longer exhibited a pedal reflex. Bronchoalveolar lavage
fluid (BALF) was obtained by washing the lungs with 2 mL
of 3 mmol/L EDTA in PBS in two aliquots of 1 mL each.
The cellular composition of BALF was determined by
hemocytometer cell counts and differential counts of cy-
tospins after staining with Quick-Diff solution (Siemens;
Medical Solutions Diagnostics, Tarrytown, NY). After cen-
trifugation, the cell-free BALF supernatant was recovered
and stored at 80°C for future use to determine levels of
cytokines and lung tissue damage.
Histological Analyses
Lungs used for histological analyses were instilled and
fixed in 10% buffered formalin phosphate (Fisher Scien-
tific, Fairlawn, NJ) for 24 hours. Paraffin-embedded lung
sections (5 m thick) were stained with H&E and evalu-
ated under a microscope (Eclipse E800; Nikon Inc., Mel-
ville, NY) at 10 and 60 objective magnification.
Survival and Determination of Bacterial Load
Mice were monitored bidaily up to 96 hours after infection.
Lung bacterial burden was determined based on the
counted number of colony-forming units (CFUs) cultured
out of 100 L of serially diluted whole lung homogenates
(LHs) on tryptic soy agar (TSA) plates at 37°C in 5% CO2.
Plated colonies were counted after an overnight incubation.
In Vivo Depletion Studies
Mice previously dosed with PCN or PBS were i.p. injected
with anti-CD11c monoclonal antibody (mAb) [HB224/
N418; for depletion of AMs and dendritic cells (DCs)] or
anti-Ly6G mAb (1A8; for depletion of neutrophils), both
obtained from BioXcell (West Lebanon, NH). The total
volume of 500 L (containing 250 g of either Ab) was
delivered by injection on days3,1, and 0 in relation to
MRSA infection (day 0). Cell depletion was verified by
flow cytometry at sacrifice and was determined to be at
least 98% efficient for depletion of Ly6G and 97%
efficient for depletion of CD11c cells in both PCN- and
PBS-dosed mice.
Neutrophil Preparation, Adoptive Transfer, and
Trafficking into the Lungs
Neutrophils were isolated from the BM of naïve BALB/c
mice by Percoll gradient, as previously described.34Briefly, BM was flushed from dissected tibias and femurs,
resuspended in HBSS (Mediatech Inc., Herndon, VA),
supplemented with 0.1% bovine serum albumin and 1%
glucose, and filtered through a 70-m nylon cell strainer
(BD, Franklin Lakes, NJ) to remove clumps and bone
particles. BM cells were centrifuged (600  g, 10 min-
utes) and resuspended in 45% Percoll PLUS solution (GE
Healthcare Bio-Sciences Corp, Piscataway, NJ). The Per-
coll gradient was prepared by layering the polypropylene
tube with 81%, 62%, 55%, and 50% of Percoll solution in
HBSS. The BM cells in 45% Percoll were carefully sus-
pended on a top of the gradient. After centrifugation
(1600  g, 30 minutes), the neutrophil fraction (band
between 81% and 62% Percoll gradient) was carefully
removed and washed twice with HBSS. The purity of the
neutrophil fraction was confirmed by microscopic exam-
ination of cells after the Diff-Quick staining procedure and
was assessed to be 97% pure. Purified neutrophils
were labeled with Vybrant-DiI (Molecular Probes, Eu-
gene, OR) dye, according to the manufacturer’s recom-
mendations. Mice were dosed nasally with PCN or PBS
for 5 consecutive days. One week after the last dose,
mice were infected with MRSA and, 1 hour later, adop-
tively transferred through tail vein injection with 1  107
Vybrant-labeled neutrophils. At 4 hours after adoptive
transfer, mice were sacrificed. The number of Vybrant
cells in BALF was determined by fluorescence-activated
cell sorting (FACS).
Cytokine Analyses
Cytokine analyses were performed on cell-free BALF.
Levels of interferon-, tumor necrosis factor (TNF)-, IL-6,
and monocyte chemoattractant protein (MCP)-1 were de-
termined by Cytometric Bead Array (BD Bioscience, San
Jose, CA), according to manufacturer’s recommenda-
tions, and analyzed by BD LSRII Flow Cytometer (BD
Bioscience) using BD Cytometric Bead Array analysis
software. Levels of IL-13 and IL-4 were determined by a
sandwich enzyme-linked immunosorbent assay kit (Ready-
SET-Go; eBioscience, San Diego, CA). BALF samples were
tested in triplicate.
Flow Cytometry
A single-cell suspension was obtained by centrifugation
of BALF. Red blood cells were lysed with AKC Lysis
Buffer (150 mmol/L NH4Cl, 1 mmol/L KHCO3, and 0.1
mmol/L Na2EDTA; pH 7.2 to 7.4) in room temperature for
5 minutes. Cells were washed with PBS twice and
blocked with Fc receptor block (2.4G2 hybridoma made
in house) for 20 minutes at room temperature. Cells were
stained with fluorochrome-labeled antibodies to extracel-
lular markers: CD11c (clone N418; eBioscience), CD11b
(clone M1/70; eBioscience), F4/80 (clone BM8; eBiosci-
ence), major histocompatibility complex (MHC) II (clone
M5/114.15.2; eBioscience), and CD206 (clone MR5D3;
AbD Serotec, Raleigh, NC). After a 30-minutes incuba-
tion, cells were washed twice in FACS buffer (1% fetal
bovine serum/PBS) and stained with streptavidin–allo-
phycocyanin for 30 minutes. After staining for extracellu-
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in 4% paraformaldehyde for 20 minutes. Fixed cells were
washed once in FACS buffer and in 0.2% saponin made
in FACS buffer, and they were stained for 30 minutes with
phosphatidylethanolamine-conjugated Abs to mouse IL-13
(clone eBio13A; eBioscience) or with rat IgG1 isotype con-
trol Ab (clone eBRG1; eBioscience). Samples were ac-
quired on FACSCanto running FACSDiva software (both
obtained from BD Bioscience). Approximately 50,000
events were routinely acquired per sample. FlowJo software
(Tree Star, Inc., Ashland, OR) was used for analysis.
Cell Selection, Bacterial Killing, and Bacterial
Uptake Assays
A single-cell suspension obtained after red blood cell
lysis and filtration (30 m) of LH was run through mag-
netic-activated cell sorting (MACS)–positive selection
columns to obtain pure Ly6G and Ly6G cell popula-
tions (97% and 98% purity, respectively). In separate
experiments, LH cells were first selected for CD11c
cells (positive MACS CD11c selection) and the CD11c
cells were subsequently depleted of Ly6G cells by
MACS Ly6G depletion columns (97% purity). The purity
of all fractions was confirmed by FACS, according to
manufacturers’ recommendations.
Bacterial Killing Assay
For these experiments, designated populations of cells
were plated in a 1:1 ratio with normal mouse serum
(NMS)–opsonized MRSA (50% NMS, 30 minutes, 37°C,
5% CO2) on NMS-coated flat-well culture plates (100%
NMS, 30 minutes, 37°C, 5% CO2). The killing assay was
conducted at 37°C for 1.5 and 3 hours. After this time,
0.1% saponin was added to each well to release inter-
nalized bacteria and total CFUs were determined for
each experimental sample by plating the 10-fold dilutions
on TSA plates. In the experiments in which two different
variants of the LAC strain were used (in vivo, MT1263
erythromycin-sensitive LAC; and in vitro, WT LAC eryth-
romycin resistant), the bacterial burden was evaluated by
plating on TSA/erythromycin plates (25 g/mL).
Bacterial Uptake Assay
This assay was performed as previously described.35
Briefly, cells isolated from BMs of mice dosed with PCN
and PBS (78% polymorphonuclear cells, as determined
by differential count) were plated on tissue culture plates
previously incubated at 37°C for 30 minutes with 100%
NMS or heat-inactivated NMS or incubated without se-
rum. Cells were left to adhere to the wells for 15 minutes
at room temperature, followed by a 10-minute incubation
on ice to prevent activation. NMS-opsonized, heat-inac-
tivated NMS–opsonized, or not opsonized MRSA was
added in a 1:1 ratio to the wells, and plates were syn-
chronized by centrifugation at 8°C, 500  g for 7 min-
utes.35 After synchronization, cells were incubated at
37°C for 30 minutes. The uptake of bacteria was stoppedafter 30 minutes, and 40 g/mL of gentamicin was added
to each well to kill the extracellular bacteria. Subse-
quently, total supernatants were removed by aspiration
and cells were resuspended in 0.1% saponin solution to
allow the release of intracellular bacteria. Wells contain-
ing MRSA only (but no mammalian cells) were used as a
baseline for gentamicin killing of extracellular bacteria.
Statistical Analyses
The differences between treatment groups were ana-
lyzed using the Student’s t-test or analysis of variance.
For the differences in survival, Kaplan-Meier curves were
plotted and analyzed using GraphPad Prism software,
version 4.0 (GraphPad, La Jolla, CA). Statistical differ-
ences of P  0.05 were considered significant.
Results
Nasal Administration of PCNs Protects from
Pulmonary MRSA Infection
Our previous studies14 indicated that nasal administra-
tion of a type of VLP, PCN, prevented body weight loss
and significantly reduced lung viral titers in mice infected
with murine-adapted influenza or severe acute respira-
tory syndrome viruses. Herein, we determined whether
nasal administration of PCN prevented mortality associ-
ated with pulmonary MRSA infection. WT mice dosed five
times with PCN and rested for a week before MRSA
infection, compared with PBS-dosed mice, showed more
than a millionfold reduction in bacterial titers in the lungs
(Figure 1A). At 72 hours after infection with 5  107 CFUs
of MRSA per dose, we isolated 1.9  103 CFUs of bac-
teria from the lungs of PCN-dosed mice and 1.2  109
CFUs of bacteria from the lungs of PBS-dosed mice.
Significant decreases in bacterial burden in spleen, liver,
and kidney were observed in PCN-dosed mice when
compared with PBS-dosed mice (see Supplemental Fig-
ure S1 at http://ajp.amjpathol.org). Interestingly, the blood
of both PCN- and PBS-dosed mice was virtually free of
bacteria up to 72 hours after infection and over the range
of challenge doses used in multiple experiments (5 107
to 5  108 CFUs; data not shown). The reduction of lung
bacterial burden directly correlated to survival of all PCN-
dosed mice (Figure 1B). In contrast to PCN-dosed mice,
the mortality of PBS-dosedmice reached50% at 24 hours
after infection, which was directly associated with high bac-
terial burden in lungs. The mortality rate of PBS-dosed mice
was dependent on the infectious dose and varied between
approximately 50% survival at 72 hours for PBS-dosed
BALB/c mice infected with 5  107 CFUs and 20% sur-
vival for these mice when infected with 5  108 CFUs of
MRSA. In contrast to PBS-dosed mice, PCN-dosed BALB/c
mice were entirely protected fromMRSA-related mortality in
all dose regimens tested (5  107 to 5  108 CFUs).
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Burden in Lungs of MRSA-Infected Mice
To determine whether induced protection against MRSA
pneumonia was specific to PCN, we investigated whether
P22 VLPwas also protective. The P22 VLPwas derived from
the P22 bacteriophage that infected Salmonella.36,37 This
VLP consisted of 420 identical copies of the P22 coat pro-
tein (each 45.5 kDa); it did not contain nucleic acids and,
thus, was not infectious. Nasal administration of P22 VLP
before MRSA infection prevented mortality and reduced
bacterial burdens in the lungs, similar to PCN administration
(see Supplemental Figure S2 at http://ajp.amjpathol.org).
PCN Administration Shortly after MRSA
Challenge Resolves Pneumonia and
Protects from Mortality
Next, we investigated whether PCN, given after exposure
to MRSA infection, also protected mice from lethal MRSA
pneumonia. Indeed, intranasal therapy with PCN started
1 hour after MRSA challenge, and repeated again at 7
and 19 hours after infection, significantly reduced bacte-
rial burden (1000-fold reduction) and prevented mor-
tality (Figure 1, C and D).
The Early Events of the First 12 Hours after
MRSA Infection Are Crucial for Disease
Resolution in PCN-Dosed Mice
To determine how soon after MRSA infection PCN admin-
istration began to exert its protective effects, PCN-dosed
mice were sacrificed at designated time points after
MRSA (Figure 2). By 12 hours after infection, a 10-fold
difference in bacterial burden was present between PCN-
and PBS-dosed mice; by 72 hours, the lungs of PCN-dosed mice showed more than a millionfold reduction in
bacterial burden when compared with PBS-dosed mice
(Figure 2A). This decline of bacterial numbers in PCN-
dosed mice was coupled with increased numbers of neu-
trophils and macrophages in the first 12 hours after
MRSA infection (Figure 2, B and C). Neutrophils were
absent in the lung lavages of PCN- and PBS-dosed mice
at infection (0 hours). Significantly more macrophages
were present in the BALF of PCN-dosed mice than in the
PBS-dosed mice at infection. At 3 hours after infection,
the numbers of macrophages in PCN-dosed mice re-
mained significantly higher when compared with PBS-
dosed mice, but were notably reduced when compared
with uninfected PCN-dosed mice. This decline was most
likely a result of migration of macrophages to the lung
parenchyma or more firm adherence to alveolar epithe-
lium, a phenomenon described originally by Sonozaki
and Cohen38 as a macrophage disappearance reaction.
In PCN-dosed mice, neutrophils and macrophages re-
mained elevated between 3 and 12 hours after infection,
but were reduced by 24 hours (Figure 2, B and C). After
24 hours, and in compliance with the return of homeo-
static conditions in the lungs of PCN-dosed mice, neu-
trophil numbers were reduced to trace levels, whereas
AMs repopulated the lung. In contrast to PCN-dosed
mice, the numbers of neutrophils in PBS-dosed mice
increased steadily until after 48 hours of infection. The
numbers of macrophages in PBS-dosed mice did not
start to increase until 48 hours after infection (Figure 2C).
Bacterial burden in the lungs of PBS-dosed mice re-
flected the delayed and/or inefficient macrophage and
neutrophil responses and remained high throughout the
experiment (Figure 2A).
Successful clearance of MRSA required an inflamma-
tory response, but an excess of inflammation is respon-
sible for tissue damage and decreased survival of MRSA-
Figure 1. Administration of VLPs protects
against MRSA pneumonia. A and B: Female
BALB/c mice are nasally dosed five times every
other day over 2 weeks (arrow) with PCN or
PBS. One week after the last dose, mice are
challenged with MRSA. C and D: Mice are in-
fected with MRSA and then treated with PCN or
PBS three times: 1, 7, and 19 hours after infec-
tion. A and C: The bacterial burden in lungs is
determined 72 hours after infection. B and D:
The survival of mice is monitored daily. Each
experiment is repeated three times. The mean 
SD from 9 to 15 mice per group (representing
three combined independent experiments) is
shown. **P  0.01, ***P  0.001 versus PCN-
dosed mice.infected mice.39,40 In this regard, the levels of lactate
repeate
, PCN; w
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infected PCN-dosed mice remained low throughout the
disease, whereas in PBS-dosed mice, these levels were
increasing until 48 hours after infection (see Supplemen-
tal Figure S3, A and B, at http://ajp.amjpathol.org). In
addition, starting at 6 hours after MRSA infection, levels of
albumin in BALF of PBS-dosed mice were significantly
increased when compared with PCN-dosed mice. This
was important because, at 6 hours after infection, no
differences in lung bacterial burden were seen between
PCN- and PBS-dosed mice. Therefore, the lack of in-
creases in albumin in PCN-dosed mice was indicative of
reduced host response-mediated tissue damage in PCN-
dosed mice. There were no statistical differences in BALF
levels of TNF-, interferon-, IL-6, and MCP-1 in the first
6 hours after MRSA infection between PCN- and PBS-
dosed mice (Figure 2D). Between 12 and 24 hours after
MRSA infection, when the bacterial burdens in PCN-
dosed mice were significantly less, the levels of these
inflammatory cytokines started to decline. However, in
PBS-dosed mice, these cytokines remained high (IL-6
and TNF-) or continued to increase (MCP-1), which was
associated with the lack of infection resolution and con-
sistently high bacterial burden in the lungs of these mice
Figure 2. PCN reduces bacterial burden and down-regulates harmful inflam
or PBS a week before MRSA infection, and were sacrificed at the designated
on sacrifice. Numbers of neutrophils (B) and mononuclear cells (C) are enum
cytokines TNF-, interferon (IFN)-, IL-13, IL-6, and MCP-1. Experiments are
0.05, **P  0.01, and ***P  0.001 versus PCN-dosed mice. Black bars/dots(Figure 2). Interestingly, of the anti-inflammatory cyto-kines tested, only levels of IL-13 were significantly ele-
vated in the BALF of PCN-dosed mice, up to 8 hours after
infection (Figure 2D).
PCN Reduces Lung Tissue Pathology
In concurrence with decreased levels of LDH and albu-
min and more efficient clearance of bacteria by innate
cells in PCN-dosed mice, we observed that at 20 hours
after MRSA infection, PCN-dosed mice showed greatly
reduced signs of tissue damage, as evaluated by stain-
ing of lung sections with H&E (Figure 3). In agreement
with our previous report,14 iBALT was present in PCN- but
not in PBS-dosed mice, in association with airways and
blood vessels (Figure 3). Phagocytic cells in the lung
parenchyma of PCN-dosed mice were intact; at 20 hours
after MRSA infection, these cells consisted predomi-
nantly of mononuclear cells that presumably were return-
ing to the lung to re-establish tissue homeostasis (Figure
3). In contrast to PCN-dosed mice, phagocytes in the
lungs of PBS-dosed mice were often disrupted and filled
with bacteria (Figure 3). The vasculature of these mice
was greatly congested and showed signs of interstitial
in the first 24 hours after infection. Mice are dosed five times daily with PCN
ints. A: The LHs are evaluated for bacterial growth. B–D: BALF is collected
by differential count. D: Cell-free supernatant is evaluated for production of
d three times. The mean  SD of five to six mice per group is shown. *P 
hite bars/dots, PBS.mation
time po
eratededema (Figure 3).
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Subsides between 3 and 5 Weeks after
Treatment
To determine how long PCN-mediated protection per-
sisted, PCN- or PBS-dosed mice were infected with 5 
107 CFUs of MRSA at 1, 2, 3, or 5 weeks after PCN or PBS
treatment. Mice infected with MRSA either 1 or 2 weeks
after PCN treatment showed significantly improved bac-
terial clearance (4 Log10) when compared with PCN-
dosed mice rested for either 3 or 5 weeks before chal-
lenge (5 Log10; see Supplemental Figure S4 at http://
Figure 3. PCN protects mice from MRSA-induced lung tissue pathology.
C57BL/6 mice are nasally dosed with PCN or PBS five times daily and
challenged with 1  108 CFUs of MRSA a week later. At 20 hours after MRSA
infection, mice are sacrificed and their lungs are fixed in formalin. Embedded
sections are then stained with H&E and analyzed by microscopy. Pictures of
representative lung sections from PCN- and PBS-dosed mice, taken using
10 and 60 magnification objectives, are shown. Arrows, iBALT (10
PCN picture) and phagocytes filled with bacteria or disrupted phagocytes
(60 PBS picture). Arrowheads, interstitial congestion and edema (60
PBS picture).ajp.amjpathol.org). No difference in bacterial burden was
observed between PCN-dosed mice that were infected
with MRSA at either 3 or 5 weeks after treatment, but
PCN-dosed mice at all time points showed improved
bacterial clearance when compared with their respective
PBS-dosed MRSA-infected control mice.
Different Phenotypes of CD11c Macrophages
and DCs Are Induced in Response to MRSA
Infection in the Lungs of PCN-Dosed Mice
Our results, presented in Figure 2, suggested a role for
macrophages in PCN-mediated protection from MRSA. In
an effort to define the phenotype and kinetics of macro-
phages, which in a steady-state lung expressed
CD11c,41 FACS analyses were performed on cells iso-
lated from BALF (Figure 4) and LHs (data not shown) of
mice infected with 5  107 CFUs of MRSA. By gating on
the total live cells (confirmed by staining with 7-amino-
actinomycin D), we confirmed that at time 0 hours (before
MRSA infection), approximately 90% of the cells recov-
ered in the BALF of both PCN- and PBS-dosed mice were
CD11c (Figure 4A and Table 1). More important, even
though 90% of cells in the BALF of PBS-dosed mice
were CD11c, the absolute number of these cells repre-
sented just a fraction of CD11c cells in the BALF of
PCN-dosed mice (Table 1). Early after MRSA infection,
the percentage of cells expressing CD11c significantly
decreased in the BALF of PBS-dosed mice to approxi-
mately 40% at 3 hours after infection and to 10% at 24
hours after infection (Figure 4A). In contrast to PBS-
dosed mice, in the BALF of PCN-dosed mice, CD11c
cells remained at approximately 70% throughout the in-
fection. CD11b cells that were virtually absent in PCN-
and PBS-dosed mice before infection (Figure 4A: at 0
hours, 6% of CD11b cells) increased significantly af-
ter infection in PBS-dosed mice (approximately 50% at 3
Figure 4. CD11c macrophages and DCs are
induced by PCN administration. Mice are dosed
five times daily with PCN or PBS a week before
MRSA infection. Mice are sacrificed at designated
time points after infection, and cells isolated
from BALF are stained and analyzed by FACS.
The gating strategy is as follows. A: The live cells
gate is set on FCS (forward scatter; representing
cell volume) versus SSC (side scatter; represent-
ing the inner complexity of the particle like gran-
ularity of a cell). Staining for CD11c versus
CD11b is determined by gating total live cells.
Representative FACS plots are shown. B: The
expression of SiglecF is evaluated on live
CD11c F4/80 or CD11c F4/80 cells. C: Live
cells are gated for F4/80 cells and then for
CD11c versus MHCII cells. CD11cMHCIIlow
AMs are shown for PCN-dosed mice, and
CD11cMHCIIhigh DCs are shown for PBS-
dosed mice. D: In an independent experiment,
the presence of M1 (CD11cCD206) and M2
(CD11cCD206) cells is determined after gat-
ing on live F4/80 cells. Each panel represents
the results from a single experiment (mean SD
from five mice per group). Each experiment is
repeated two to three times. **P  0.01, ***P 
0.001 versus PBS-dosed mice.
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BALF of PCN-dosed mice, these cells peaked at approx-
imately 20% at 3 hours after infection and these percent-
ages remained unchanged until 24 hours after infection
(Figure 4A). Despite their lower percentage, the numbers
of CD11b cells were similar between PCN- and PBS-
dosed mice (data not shown).
In the lungs, cells that expressed CD11c could be AMs
and/or DCs.42 We used multiple staining strategies to
distinguish between AMs and DCs, including either dif-
ferential expression of SiglecF43–45 and F4/8042 (Figure
4B) or various expression levels of MHCII46 (Figure 4C).
We confirmed that CD11cMHCIIlow cells were also
SiglecF (and, thus, were AMs) and CD11cMHCIIhigh
cells were SiglecF (and, thus, were DCs; data not
shown). When compared with PBS-dosed mice, the num-
bers of total CD11c cells, and CD11c F4/80 SiglecF
AM and SiglecF DCs, were significantly higher in PCN-
dosed mice before and shortly after MRSA infection (Fig-
ure 4, A and B, and Table 1). Even though numbers of
AMs (CD11cSiglecF cells in Figure 4B) remained sig-
nificantly lower in PBS-dosed mice until 48 and 72 hours
after infection, the numbers of DCs (CD11cSiglecF
cells in Figure 4B and CD11cMHCIIhigh cells in Figure
4C) in these mice increased rapidly at 12 hours after
infection and significantly exceeded the numbers of DCs
in PCN-dosed mice at later points after infection (Figure
4B and Table 1). M1 macrophages are considered to be
the short-term responders to infections, whereas the M2
phenotype is usually associated with wound healing and
less damaging chronic inflammatory responses.47,48 We
observed that, in PCN-dosed mice at 4 hours after MRSA
infection, there was threefold more M1 (CD11c CD206)
than M2 (CD11c CD206) macrophages (Figure 4D). At 8
hours after infection in PCN-dosed mice, the dominance of
M1 phenotype was smaller, yet still significant (twofold more
Table 1. Kinetics of CD11c Cells in the BALF of PCN- and PBS
Time after
MRSA
(hours)* Treatment†
% of Total
F4/80CD11c
cells‡
No. of total
F4/80CD11c
cells§
(S
0 PCN 85.6  3.4 4.2  105
0 PBS 91.0  2.4 0.4  105
3 PCN 42.66  15.2†† 1  105**
3 PBS 21.5  4.2 0.14  105
6 PCN 15.6  5.9 1.2  105
6 PBS 11.34  3.6 0.33  105
12 PCN 18.3  2.2** 3.8  105
12 PBS 3.74  1.22 0.8  105
24 PCN 30  11** 0.9  105††
24 PBS 4.32  1.1 0.24  105
48 PCN 41.6  9.4** 3.2  105
48 PBS 6.8  2.9 0.9  105
72 PCN 47.9  8.9** 4.5  105††
72 PBS 15.2  3.9 2.4  105
*A week after the last PCN or PBS treatment, mice were infected with
†BALB/c mice were intranasally dosed with PCN or PBS and rested f
‡BALF cells were stained and analyzed by FACS. The gating strategy
§The absolute numbers of cells were calculated by multiplying the pe
¶SiglecF and SiglecF were determined by gating on CD11c cells
P  0.01 versus PBS-dosed mice.
**P  0.001 versus PBS-dosed mice.
††P  0.05 versus PBS-dosed mice.of M1 macrophages); at 24 hours after infection, when thebacterial burden in the lungs of PCN-dosed mice was fur-
ther diminishing (Figure 2A), theM1 prevalence over theM2
phenotype was fivefold. Contrary to PCN-dosed mice, PBS-
dosed mice had almost threefold as many M2 macro-
phages as M1 at 4 hours after infection. At 8 hours after
infection in these mice, the numbers of M1 and M2 macro-
phages in BALF were similar, but at 24 hours after infection,
the numbers of M2 cells again exceeded the numbers of
M1 cells (Figure 4D).
CD11c Cells and Neutrophils from PCN-
Dosed Mice Are More Efficient in Killing MRSA
Our results thus far suggested a role for macrophages
and neutrophils in PCN-induced protection. Thus, we de-
termined whether these cells in PCN-dosed mice were
better in killing MRSA than cells from PBS-dosed mice.
Morphological assessment of these cells at 3 hours after
MRSA infection indicated that mononuclear cells in the
BALF of PCN-dosed mice were, for the most part, intact
and appeared to contain bacteria (Figure 5A). At the
same time, plasma membranes of mononuclear cells in
the BALF of PBS-dosed mice were largely disrupted and,
consequently, cell-free portions of the BALF from these
mice contained frequent bacteria (Figure 5A). At 3 hours
after infection, in contrast to mononuclear cells in the
BALF of PCN-dosed mice, the morphological appear-
ance of mononuclear cells in the BALF of PBS-dosed
mice suggested that these cells underwent necrosis.
Results described in Figure 4D showed that, in con-
trast to macrophages in PBS-dosed mice, these cells in
PCN-dosed mice were predominantly M1. By applying
cell isolation techniques, we obtained 97% pure popu-
lation of CD11cLy6G cells that were F4/80, as deter-
mined by FACS, and 90% pure population of F4/80
Mice
. of
CD11c
AMs¶
% of (SiglecF
CD11c) AMs
% of (SiglecF
CD11c) DCs¶
No. of (SiglecF
CD11c) DCs
105 80.9  4.7 19.1  4.7** 0.7  105**
105 94.2  1.6 5.8  1.6 0.03  105
105** 81  1.8 19  1.8 0.2  105
105 50.4  6.9 49.6  13.9 0.08  105
105 78.1  7.0 11.9  3.7†† 0.2  105
105 88.1  3.7†† 21.9  7.0 0.04  105
105 63.86  10.7 36.1  13†† 1.4  105
105 35.32  7.5 64.68  14.6 1.6  105
105†† 72.58  4.9 27.4  4.9 0.3  105
105 49.32  6.7 50.68  11.7 0.3  105
105†† 69.1  5.1** 30.9  5.1** 1.0  105††
105 29.09  6.9 70.91  12.0 2.1  105
105 71.72  7.2** 28.28  7.3** 1.0  105††
105 34.4  8.3 65.6  8.3 1.5  105
.
ek.
s described in the legend to Figure 4.
e of live cells by the cell number counted under hemocytometer/100%.-Dosed
No
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3.4 
0.4 
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dosed but not infected mice (Figure 5B). Next, we inves-
tigated which of these cell subsets were better in killing
MRSA. As expected, PCN-CD11c cells were more effi-
cient than DN cells in killing bacteria in vitro (killing effi-
cacy of CD11c cells, approximately 80%; DN cells,
approximately 35%; Figure 5B). Interestingly, no differ-
ence in bacterial killing was observed between CD11c
and DN cells isolated from not infected PBS-dosed mice,
and either of these cells killed only approximately 30% of
bacteria. In the following experiment, we isolated Ly6G
and Ly6G cells from the lungs of PCN- or PBS-dosed
mice that, 2.5 hours earlier, were infected with erythro-
mycin-sensitive MRSA. Similarly, when lung Ly6G neutro-
phils and Ly6G cells isolated from erythromycin-MRSA–
infected PCN- or PBS-dosed mice were examined for their
ability to kill WT MRSA, both of these cell subsets from
PCN-dosedmice weremore effective in killing bacteria than
the respective cell subsets from PBS-dosed mice (Figure
5C). Moreover, Ly6G cells were better in killingMRSA than
Ly6G cells in both experimental groups.
Within 1 hour after nasal installation, the PCN was
found in respiratory lymph nodes (tracheobronchial and
cervical) and, in 24 hours, they were nearly completely
gone from the body.17 To determine whether PCN-medi-
Figure 5. CD11c cells and neutrophils from PCN-dosed mice are more effic
five times daily with PCN or PBS a week before MRSA infection. A microgra
hours after MRSA infection. B: Mice are dosed with PCN or PBS and are sacrif
(DN) cells by MACS columns. After selection, cells are incubated in a 1:1 ratio
by an overnight incubation. The mean and SD of duplicate samples from th
are infected with erythromycin-sensitive MRSA mutant, and 2.5 hours later,
in a 1:1 ratio with WT MRSA for 3 hours. The CFUs of WT MRSA are determi
isolated a week after the last PCN or PBS administration are plated in a 10:1
with NMS or heat-inactivated NMS or not opsonized. D: For the bacterial u
extracellular bacteria. The CFUs of bacteria taken up by BM cells are measu
*P  0.05, **P  0.01, and ***P  0.001 versus PCN-dosed mice; †P  0.05 v
MRSA-only control. Experiments are performed at least twice, with a similaated protection from MRSA infection was limited to thelung environment, we isolated BM cells from mice that
had been dosed with PCN or PBS a week earlier. The BM
cells were then incubated with MRSA to determine the
efficiency of uptake and killing of bacteria in vitro. After 30
minutes of incubation, BM cells from PCN-dosed mice
took up twofold more bacteria than BM cells from PBS-
dosed mice (Figure 5D). The rate of internalization was
highest when bacteria were opsonized with NMS, al-
though even unopsonized bacteria and bacteria op-
sonized with heat-inactivated NMS were also internalized
and killed by BM cells from PCN-dosed mice (Figure 5, D
and E). When compared with the background MRSA
levels (bacteria incubated alone and treated with genta-
micin), similar numbers of bacteria were retrieved from
wells incubated with BM cells from PBS-dosed mice,
indicating that, during the 30 minutes of incubation time,
BM cells from PBS-dosed mice failed to efficiently take up
MRSA (Figure 5D). Interestingly, after 3 hours of incuba-
tion, BM cells from PBS-dosed mice killed MRSA, al-
though not as well as BM cells derived from PCN-dosed
mice (Figure 5E). During the 3 hours of in vitro incubation,
BM cells from PCN-dosed mice killed, on average, two to
three times more bacteria than these cells from PBS-
dosed mice, and killing of MRSA by BM cells from PCN-
dosed mice was enhanced, although not fully dependent,
illing MRSA than the respective cells from PBS-dosed mice. A:Mice are dosed
ide sections containing BALF cells isolated from PCN- or PBS-dosed mice 3
eek after the last dose. LHs are selected for CD11c cells and CD11cLy6G
SA for 1.5 hours, and CFUs are determined by plating on TSA plates, followed
ur mice per group is shown. C: One week after the PCN or PBS dose, mice
sacrificed. LHs are selected for Ly6G and Ly6G cells that are incubated
r overnight incubation on TSA/erythromycin plates. D and E: Total BM cells
1:1 (E) bacteria:BM cell ratio. The MRSA used for experiments is opsonized
ssay, after a 30-minute incubation, gentamicin is added to each well to kill
lating. E: Bacterial killing by BM cells is assessed after a 3-hour incubation.
e respective Ly6G or Ly6G cells from PCN-dosed mice; ‡P  0.05 versusient in k
ph of sl
iced 1 w
with MR
ree to fo
mice are
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(D) or
ptake a
red by pon opsonization by complement (Figure 5E).
mice p
 0.00
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Independent of Adaptive Immunity
We previously observed that the accelerated protection
against viruses that was induced by PCN administration
was dependent, in part, on the formation of iBALT, be-
cause the PCN administration to mice deficient in adap-
tive immunity, such as SCID, B-cell–deficient muMT, or
WT mice depleted of CD4 T cells, did not prevent influ-
enza infection.14 To discern whether PCN protection
against MRSA also required functional adaptive immu-
nity, PCN-dosed SCID mice were challenged with 5 
107 CFUs of bacteria. SCID and WT mice dosed with
PCN before infection showed a similar significant reduc-
tion in the lung bacterial burden at 24 and 48 hours after
Figure 6. PCN-mediated protection against MRSA depends on innate imm
infection. A: The bacterial burden is evaluated in murine lungs 24 hours afte
anti-CD11c mAb or anti-Ly6G mAb on day3,1, and 0, in relation to MRSA
represent individual mice from one of two independent experiments. D: Mice
(left panel), and numbers of CD11c cells in BALF are determined by FACS
(right panel). The mean  SD of five mice per group is shown and repre
infection, mice are adoptively transferred with Vybrant-DiI–labeled naïve ne
the BALF is determined by FACS. The mean and SD of eight mice per group
after infection. The bacterial burden in the lungs is determined (left pan
determined by differential counts (right panel). The mean  SD of five
experiments. *P  0.05, **P  0.01, ***P  0.001 versus PBS-dosed mice; †Pinfection, when compared with their PBS-dosed litter-mates (Figure 6A and data not shown, respectively). In
addition, 100% of PCN-dosed SCID and WT mice sur-
vived MRSA infection (Figure 6B), whereas only 40% of
PBS-dosed SCID and WT mice survived to 24 hours after
infection.
Both Ly6G Neutrophils and CD11c Cells
Are Responsible for PCN-Mediated
Protection from MRSA
Although neutrophils are regarded to be the early and
predominant cells responsible for fighting bacterial infec-
tions, including MRSA,49–51 increasing importance is as-
signed to CD11c cells46 in such killing. To discriminate
ls. Mice are dosed five times daily with PCN or PBS a week before MRSA
ion. B: Survival is evaluated during a 2-day period. C: Mice are treated with
n, and lung bacterial burden is evaluated 24 hours after infection. The results
rificed 24 hours after infection. Bacterial burden in the lungs was determined
ining with fluorochrome-labeled anti-CD11c mAb before and after infection
e results of one of two independent experiments. E: At 1 hour after MRSA
ls, and 4 hours later, mice were sacrificed. The number of Vybrant cells in
ed two independent experiments) is shown. F: Mice are sacrificed 24 hours
numbers of polymorphonuclear and mononuclear cells in the BALF are
er group is shown and represents the results of one of two independent
1; ‡P  0.05 versus PCN-dosed WT mice.une cel
r infect
infectio
are sac
after sta
sents th
utrophi
(combin
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AJP July 2012, Vol. 181, No. 1mediated protection against MRSA, we depleted either
Ly6G (neutrophils) or CD11c cells (macrophages and
DCs) from PCN-dosed mice on day 3, 1, and 0, be-
fore MRSA infection. In mice dosed with PCN, depletion
of either neutrophils or CD11c cells impaired resistance
to infection, because the bacterial burdens in the lungs of
depleted mice were significantly greater than the bur-
dens in the lungs of PCN-dosed mice treated with isotype
control Abs (Figure 6C, P  0.05). Moreover, in PCN-
dosed mice, neutrophil depletion resulted in much higher
bacterial numbers than did CD11c cell depletion (P 
0.05), indicating the importance of neutrophil function in
PCN-induced protection. Depletion of CD11c cells from
PBS-dosed mice did not affect the lung CFU counts when
compared with nondepleted PBS-dosed mice. However,
the lungs of PBS-dosed mice depleted of neutrophils
showed increases in CFUs when compared with PBS-
dosed mice not depleted of neutrophils (P  0.001), indi-
cating the importance of neutrophils in controlling MRSA,
even in the absence of PCN. More important, regardless of
whether the groups of mice were undepleted, depleted of
neutrophils, or depleted of CD11c cells, the PCN-dosed
mice were always more resistant to MRSA pneumonia than
the PBS-dosed mice.
Uncompromised Infiltration of Monocytes Is
Required for PCN-Mediated Protection Against
MRSA
Depletion of CD11c cells in PCN-dosed mice resulted in
a partial inhibition of PCN-induced protection against
MRSA (Figure 6C). Whether the protective CD11c cells
were recruited monocytes resulting from PCN treatment,
PCN-altered resident macrophages, or PCN-altered re-
cruited monocytes remained to be determined. CCR2 is a
receptor molecule for MCP-1.52 Consequently, mono-
cytes in CCR2 KO mice are impaired in their ability to
infiltrate inflammatory sites and, thus, recruitment of
monocytes in response to PCN treatment before MRSA
infection should also be compromised. Indeed, numbers
of CD11c cells were significantly reduced in PCN-
dosed CCR2 KO mice both before and 24 hours after
MRSA infection when compared with PCN-dosed WT
mice (Figure 6D). Also, PCN-dosed CCR2 KO mice were
less competent than the PCN-dosed WT mice in clearing
MRSA infection (Figure 6D). In this regard, at 24 hours
after infection, PCN-dosed CCR2 KO mice showed 10-
fold more bacteria in their lungs than PCN-dosed WT
mice, indicating that CCR2 signaling played a role in
PCN-induced resistance to MRSA. Interestingly, when
compared with PBS-dosed WT mice, PBS-dosed CCR2
KO mice showed elevated bacterial burden, but reduced
CD11c cell numbers, at 24 hours after infection, impli-
cating the role of recruited monocytes in clearance of
MRSA infection in these mice as well. All CCR2 KO mice,
independent of treatment, survived MRSA infection up to
96 hours, when the study was terminated (see Supple-
mental Figure S5A at http://ajp.amjpathol.org). This sug-
gested that absence of the CCR2 receptor had no effecton survival of PCN-dosed mice, and even improved the
survival of PBS-dosed mice.
PCN Enhances Neutrophil Trafficking into the
Lungs in Response to MRSA Infection
To determine whether administration of PCN enhanced
neutrophil recruitment into the lungs, mice predosed with
either PCN or PBS were infected with MRSA and, 1 hour
later, adoptively transferred with Vybrant-DiI–labeled BM
neutrophils isolated from naïve littermates. The number of
Vybrant cells in LHs of PCN-dosed mice 5 hours after
MRSA infection was significantly higher when compared
with the lungs of PBS-dosed mice (Figure 6E, P  0.01),
indicating that PCN changed the lung environment, re-
sulting in enhanced neutrophil recruitment in response to
infection. Consistent with this observation were the find-
ings of both a significant decrease of neutrophil recruit-
ment in PCN-dosed CXCR2 KO mice (Figure 6F, P 
0.001) and lower effectiveness in clearing MRSA infection
(P  0.05) compared with PCN-dosed WT mice. More-
over, the inability of PCN-dosed CXCR2 KO mice to re-
cruit neutrophils to MRSA-infected lungs decreased their
survival compared with PCN-dosed WT mice. In this re-
gard, the PCN-dosed KO mice started dying by day 4
after infection; and by 5 days after infection, 80% of
PCN-dosed CXCR2 KO mice had succumbed to MRSA
infection, whereas all of the PCN-treated WT mice sur-
vived through 5 days (see Supplemental Figure S5B at
http://ajp.amjpathol.org). More important, when com-
pared with PCN-dosed CXCR2 KO mice, PBS-dosed
CXCR2 KO mice were less effective in clearing MRSA
infection, despite the CXCR2-independent recruitment of
neutrophils to the lungs of PBS-dosed CXCR2 KO mice,
but PCN- and PBS-dosed KO mice showed a similar
lethality rate. This suggested that CXCR2 signaling was
important for PCN-induced protection against lethality
from MRSA infection, but not important for the PCN-inde-
pendent resistance to MRSA pneumonia.
IL-13 Is Required for PCN-Mediated Protection
Against MRSA
We found that levels of IL-13 were significantly elevated
in the BALF of PCN-dosed mice up to 9 hours after MRSA
infection (Figure 2D). To determine whether anti-inflam-
matory cytokines played an important role in PCN-medi-
ated protection against MRSA, we analyzed bacterial
burden in the lungs of PBS- or PCN-dosed IL-13 and IL-4
KO mice 24 hours after infection. Interestingly, no differ-
ence in bacterial clearance from the lungs was observed
between PCN- and PBS-dosed IL-13 KO and PBS-dosed
WT mice, but when those three groups of mice were
compared with PCN-dosed WT mice, the three groups of
mice each had at least 100-fold more bacteria in their
lungs (Figure 7A). Consistent with the lack of bacterial
clearance, PCN-dosed IL-13 KO mice reached 50% mor-
tality within the first 24 hours after MRSA infection (see
Supplemental Figure S5C at http://ajp.amjpathol.org).
PCN-dosed IL-4 KO mice cleared bacteria more effi-
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well as PCN-dosed WT mice (data not shown). We also
found that CD11c cells in PCN-dosed mice produced
IL-13 at 2.5 hours after MRSA infection (Figure 7B). This
observation was further confirmed by the virtual absence
of IL-13 in BALFs of PCN-dosed WT mice that, before
infection, were depleted of CD11c cells, much like PBS-
dosed mice independent of the presence of CD11c
cells (Figure 7C). When tested, IL-4 levels were signifi-
cantly elevated in PCN-dosed undepleted mice, when
compared with PBS-dosed mice either depleted or not
depleted of CD11c cells (Figure 7D).
Discussion
We show herein that intranasal delivery of VLPs, such as
PCN, induced near complete resistance to lethal MRSA
pneumonia. Mice dosed with PCN either before or shortly
after MRSA infection were protected from mortality and
showed up to a millionfold reduction in bacterial burden,
when compared with PBS-dosed mice. Remarkably, when
mice were treated with a VLP unrelated to PCN, P22, a
similar degree of protection and recovery was observed.
This suggests that the protective effect induced by either of
the VLPs can be attributed to shared physical characteris-
tics, such as repeating protein subunits, and small size,
similar to a virus, rather than the origin of the VLP. VLPs,
because of their ability to stimulate pathogen-associated
molecular pattern recognition receptors on DCs, are effec-
tive inducers of innate, and adaptive, immunity.18–20,53
Thus, VLPs have been used predominantly for their adju-
vant properties19,21 and their ability to deliver either genet-
ically conjugated or chemically fused epitopes for the in-
duction of specific immune responses.25,54 However, their
potential role as self-proprietors of immune modulation has
not been extensively investigated, and the present data
suggest that they could be used in this regard.Because of the early resolution of MRSA infection by
more efficient neutrophils and macrophages in PCN-
dosed mice, decreased signs of cellular damage (mea-
sured by extracellular release of LDH) or tissue leaking
(measured by serum albumin level) were found in the
BALF of PCN-dosed mice. In contrast to PCN-dosed
mice, levels of albumin and LDH in the BALF of PBS-
dosed mice increased as early as 6 and 12 hours after
MRSA infection, respectively. These increases coincided
with inefficient bacterial clearance in the lungs of PBS-
dosed mice by infiltrating neutrophils and mononuclear
cells, which, as early as 2 to 3 hours after infection,
showed signs of necrosis and extracellular release of
bacteria. At 6 hours after infection, lung bacterial burden
was similar in PCN- and PBS-dosed mice; thus, in PCN-
dosed mice, the host response to MRSA caused less
lung damage, which is similar to what we found in PCN-
dosed mice infected with influenza.14 The more efficient
bacterial clearance and abridged lung damage coin-
cided with the greatly reduced lung tissue pathological
characteristics, apparent by the lack of congestion and
interstitial edema at 20 hours after MRSA infection in the
lungs of PCN-dosed, but not PBS-dosed, mice.
Up to 12 hours after MRSA infection, most cells in the
BALF of PBS-dosed mice could be classified as macro-
phages, based on their expression of SiglecF and inter-
mediate levels of MHCII. However, in PCN-dosed mice at
these time points, SiglecF/MHCIIhigh DCs accounted for
slightly 10% of CD11c cells. The role of CD11c cells
in pulmonary MRSA infections just recently gained atten-
tion.46 According to the study by Martin et al,46 clodro-
nate-induced depletion of CD11c AMs did not affect
bacterial burden in the lungs, but was associated with
increased mortality; however, when CD11c cells were
depleted in CD11c–enhanced green fluorescence pro-
tein–diphtheria toxin mice, the bacterial burden in the
Figure 7. CD11c cell-induced early IL-13 se-
cretion is important for disease resolution by
PCN-dosed mice. A: Mice are dosed five times
daily with PCN or PBS a week before MRSA
infection and sacrificed 24 hours after infection.
The bacterial burden in lungs is determined. B:
PCN- and PBS-dosed mice are infected with 1 
108 CFUs of MRSA. FACS staining is performed
on cells isolated from the BALF of these mice 2.5
hours after MRSA infection. Representative plots
of IL-13 CD11c cells are shown compared
with these CD11c cells stained with isotype
control Abs. C and D: Mice are depleted of
CD11c cells on day 3, 1, and 0, in relation
to MRSA infection, as described in the legend for
Figure 6C. Mice are sacrificed 4 hours after in-
fection, and the concentration of IL-13 (C) and
IL-4 (D) is determined in their cell-free BALF. Each
experiment is performed twice. The mean SD of
three to four mice per group from a single exper-
iment is shown. **P  0.01, ***P  0.001 versus
PCN-dosed mice.lungs increased, although no changes in mortality were
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CD11c DCs, although not numerous in the BALF, are
important for protection from MRSA pneumonia.
The altered phagocytosis of apoptotic cells in the lung
has been linked to the overwhelming inflammation that
can lead to extensive tissue damage and even autoim-
munity.55 Not surprisingly, one of the survival mecha-
nisms exploited by intracellular bacteria includes repro-
gramming of the phagocytic cells, which allows them to
escape intracellular killing. In this regard,Mtb was shown
to avoid killing by macrophages via induction of cell
necrosis rather than apoptosis.56 Also, MRSA-induced
programmed necrosis rapidly killed neutrophils, but not
bacteria.57 In our experiments, as early as 2 to 3 hours
after MRSA infection, mononuclear cells isolated from
PCN-dosed mice were intact and associated with bacte-
ria. At the same time after infection, the plasma mem-
brane of macrophages from PBS-dosed mice was al-
ready destroyed, and the remaining cell debris showed
signs of organelle swelling, all of which is usually asso-
ciated with necrosis. Furthermore, in contrast to PCN-
dosed mice, extracellular portions of the BALF of PBS-
dosed mice contained numerous bacteria, suggesting
inefficient killing by cells in PBS-dosed mice. These re-
sults implicate that lung macrophages in PCN-dosed
mice were resistant to MRSA-induced necrosis and, thus,
were better able to kill MRSA.
Enhancement of the primary immune response is re-
sponsible for PCN-induced protection against body
weight loss and reduction of viral titers in the lungs of
mice infected with either murine influenza or severe acute
respiratory syndrome viruses.14 Herein, we report that
PCN-mediated protection against MRSA infection was
entirely dependent on functional innate immunity. In this
regard, PCN-dosed SCID mice showed similar recovery
rates and nearly identical reduction of bacterial burden
as PCN-dosed WT mice, and depletion of CD4 or CD8 T
cells even further enhanced PCN-mediated protection
(data not shown). Moreover, when depleted of either neu-
trophils or CD11c cells, PCN-dosed mice were less
resistant to MRSA pneumonia. However, depletion of
neutrophils after PCN administration resulted in the loss
of more than two logs of protection and increased mor-
tality of mice, whereas CD11c depletion resulted in the
loss of less than a log of protection and had no effect on
mouse survival. There is an obvious inconsistency be-
tween how efficient CD11c cells from PCN-dosed mice
were in killing MRSA in vitro and only a moderate effect
that the depletion of these cells had on bacterial burden
in PCN-dosed mice in vivo. This discrepancy could be
attributed to the overall fewer macrophages in the lungs
when compared with neutrophils in PCN-dosed mice.
Therefore, although CD11c cells appear more efficient
in killing MRSA in vitro, neutrophils may have a greater in
vivo effect because of their prevalence in the MRSA-
infected lung.
CCR2 is a receptor molecule for MCP-1; therefore, the
trafficking of monocytes to inflammatory sites is compro-
mised in CCR2 KO mice.52 Even before MRSA infection,
the numbers of CD11c cells in CCR2 KO mice dosed
with PCN were significantly lower than the numbers ofthese cells in PCN-dosed WT mice, and were similar to
the numbers of CD11c cells in PBS-dosed WT and
CCR2 KO mice. At 24 hours after MRSA infection, the
bacterial burden of CCR2-deficient PCN-dosed mice was
significantly elevated when compared with PCN-dosed
WT mice, which is consistent with the well-established
importance of recruited monocytes in fighting pulmonary
microbial infections.7,52,58 Therefore, we concluded that
many CD11c cells in the lungs of PCN-dosed mice at
infection are newly recruited resident cells. Despite sharing
a similar FACS profile with CD11c cells in PBS-dosed
mice, these cells were recruited to the lung in response to
PCN administration; thus, they represent a diverse cell pop-
ulation, perhaps one that is more efficient in fighting bacte-
rial infection.
Neutrophils are considered the primary line of defense
against MRSA infections,49,59 although they are also ac-
tively targeted by MRSA to improve its survival within the
host.57,60,61 In our experiments, PCN-dosed WT mice
showed enhanced neutrophil recruitment, but also a
much faster decline in neutrophil numbers in the MRSA-
inflamed lung, which presumably prevented extensive
tissue damage. However, PCN-dosed CXCR2 KO mice
infected with MRSA showed increased bacterial burden
at 24 hours after infection, increased mortality, and a
deficiency of neutrophil recruitment when compared with
PCN-dosed WT mice. In contrast, CXCR2 KO mice that
received PBS had nearly identical numbers of neutrophils
as PBS-dosed WT mice. This suggests that, in contrast to
PBS-dosed mice, MRSA-induced recruitment of neutro-
phils in PCN-dosed mice was CXCR2 dependent. Be-
cause no difference in bacterial burden was observed
between PBS-dosed CXCR2 KO and WT mice at 24
hours after infection, we concluded, in agreement with
other studies,57,61 that neutrophils alone are not sufficient
in clearing MRSA infection.
Among the CD11cF4/80 cells isolated from PCN-
dosed MRSA-infected mice, the high ratio of M1
(CD11cCD206) to M2 (CD11cCD206) cells per-
sisted throughout the disease. In contrast to these mice,
most macrophages in MRSA-infected, PBS-dosed mice
showed characteristics of M2 cells. It is well described
that M1 macrophages are more efficient responders to an
acute infection, whereas the long-term stage M2 cells,
even though they cause less tissue damage, are also less
efficient in killing microbes.62 Furthermore, M2 macro-
phages can be subdivided into three subclasses (a to c),
in which M2a cells develop in the presence of IL-13/IL-4
and lipopolysaccharide enhances the M2b phenotype.63
M2a AMs supported M1 cells and promoted lung de-
fense against Pneumocystis murina.64 Interestingly, in-
duction of IL-13 and IL-4 was observed early after MRSA
infection of PCN-dosed, but not PBS-dosed, mice, sug-
gesting that M2 cells in PCN- and PBS-dosed mice can
differ in their ability to support M1 cells in response to
MRSA infection. Despite the presence of IL-13 in the
BALF of MRSA-infected PCN-dosed, but not PBS-dosed,
mice, the levels of proinflammatory cytokines remained
similar between these mice until 12 hours after infection.
After 12 hours of infection and likely as a consequence of
disease resolution in PCN-dosed mice, a sudden reduc-
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The importance of IL-13 in PCN-mediated protection from
lethal MRSA pneumonia was indicated by the lack of
recovery and disease resolution in PCN-dosed IL-13 KO
mice, the increased mortality of these mice, and the re-
alization of only partial protection in PCN-dosed IL-4 KO
mice (data not shown). IL-13 causes neutrophil activation
and recruitment via induction of IL-8–like chemoattrac-
tant on airway epithelium.65,66 The role of IL-13 in pulmo-
nary clearance of methicillin-sensitive S. aureus was re-
ported by Olszewski et al.67 In their hands, IL-13 KO mice
showed delayed clearance of bacteria, but when mice
were reconstituted with exogenous IL-13, normal clear-
ance was restored. We have determined that CD11c
cells in PCN-dosed, but not in PBS-dosed, mice are ac-
countable for the production of IL-13, whereas the pro-
duction of IL-4 was only partially dependent on the pres-
ence of CD11c cells. Which subsets of PCN-induced
CD11c cells are involved in IL-13 and/or IL-4 produc-
tion, and the exact mechanism of IL-13–dependent pro-
tection in our model, requires further investigation.
In summary, this work describes a novel approach of
priming of the lungs via administration of noninfectious
VLPs, resulting in enhanced efficacy of the innate im-
mune response, but omits the risk of tissue-damaging
inflammation that occurs with pathogen-induced altera-
tion of lung environment. Our results indicate that im-
proved uptake and killing of MRSA by neutrophils and
CD11c cells, and possibly cell-independent mechanisms,
are involved. To our knowledge, this is the first report de-
scribing the importance of CD11c cells in IL-13–depen-
dent protection from MRSA pneumonia. Our results provide
important insights into the mechanisms of host anti-MRSA
response in the lung and suggest that VLPs could be a
viable means of enhancing these mechanisms.
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